血必净联合乌司他丁治疗感染性休克临床观察

Clinical Effect of Xuebijing Combined with Ulinastatin in Treatment of Septic Shock

目的 观察乌司他丁联合血必净治疗感染性休克的效果。方法 选取40例感染性休克患者为研究对象,将其按照随机数字表法分为观察组和对照组,每组20例。对照组患者在常规治疗的基础上静脉注射乌司他丁,观察组患者在对照组疗法基础上注射血必净。观察患者的并发症发生率和病死率;采用急性生理与慢性健康评分Ⅱ(Acute Physiology and Chronic Health Evaluation Ⅱ,APACHEⅡ)评价病情的危重程度,检测降钙素原(procalcitonin,PCT)水平评价炎症程度;评价患者的治疗效果。结果 观察组患者并发症发生率、病死率低于对照组,但差异均无统计学意义(P>0.05);两组患者治疗后APACHE Ⅱ评分和PCT水平均较治疗前明显降低(P<0.05),且观察组APACHE Ⅱ评分和PCT水平降低程度均明显大于对照组(P< 0.05);观察组临床疗效优于对照组,但差异无统计学意义(P>0.05)。结论 联用血必净和乌司他丁治疗感染性休克,可提高临床疗效,但尚需大样本研究进一步证实。

Objective To investigate the clinical effect of ulinastatin combined with Xuebijing in the treatment of septic shock. Methods A total of 40 patients with septic shock were enrolled and divided into observation group and control group using a random number table, with20 patients in each group. The patients in the control group were given conventional treatment and intravenously injected ulinastatin, and those in the observation group were given Xuebijing injection in addition to the treatment in the control group. The incidence rate of complications and mortality rate were observed, and the Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ) score was used to evaluate disease severity. The level of procalcitonin (PCT) was measured to evaluate the degree of inflammation, and treatment outcome was assessed. Results The observation group had lower incidence rate of complications and mortality rate than the control group (P>0.05). Both groups had significant reductions in APACHE Ⅱ score and PCT level after treatment (P<0.05), and the observation group had significantly greater reductions than the control group (P<0.05). The observation group had a better clinical outcome than the control group (P >0.05). Conclusion Xuebijing combined with ulinastatin can effectively improve the clinical outcome of patients with septic shock, but more large-sample studies are needed.